Dual-port Trans-subclavian Thyroid Endoscopic Surgery

Launched by FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY · May 2, 2024

Keywords

ClinConnect Summary

This clinical trial is investigating a new type of surgery for patients with thyroid tumors called dual-port trans-subclavian thyroid endoscopic surgery. This method uses a smaller incision and aims to improve recovery time and cosmetic appearance compared to traditional open thyroid surgery. The study will involve 300 patients who will be divided into two groups: one group will receive the new endoscopic surgery, while the other will undergo the usual open surgery. Researchers will carefully monitor and compare the safety and effectiveness of both approaches, looking at factors like surgical complications, recovery time, and patient satisfaction with their scars.

To be eligible for this trial, participants should have thyroid cancer or benign thyroid tumors that aren't too large—specifically, tumors less than 2 cm for cancer and less than 5 cm for benign tumors. Additionally, they should be seeking improvement in their surgical scars. Patients with serious health issues or certain chronic diseases, like autoimmune disorders, may not qualify. Those who participate can expect thorough follow-up care, including assessments of their recovery and satisfaction with the surgery over three months. This trial is important as it aims to provide more evidence on the safety and benefits of this innovative surgical technique.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Thyroid cancer or benign thyroid tumors
• • Patients with a demand for incisional cosmetic improvement
• Exclusion Criteria:
• • Patients with thyroid cancer larger than 2 cm
• • benign tumors larger than 5 cm
• • Patients with severe underlying diseases
• • Patients with chronic kidney disease,
• • Patients with autoimmune diseases
• • Patients with rheumatoid arthritis